Entry Rationale
From a personal simulation perspective, I will consider entering based on the strong positive news of the clinical success of the melanoma vaccine from Moderna and Merck.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
MRNAAI Trading Journal · 2026-08-20
The Strength of the Melanoma Vaccine Theme Fueled by Exploding Clinical Expectations
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
ENTRY PRICE$62.96Entry reference price
AI PREDICTION+7.5%Predicted upside
VERIFIED RESULT125.8%125.8% up
PREDICTION GAP+118.3%pGap vs. actual result
CONFIDENCE90AI analysis confidence
Moderna and Merck's personalized cancer vaccine showed positive results in early-stage melanoma clinical trials.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
Based on my personal simulation results, I will approach the situation based on news flow and momentum, but for risk management, I will take profits if the target price of $65.53 is reached, and I will cut losses if the stop-loss price of $52.66 is breached.
Take-profit reference$65.53
Stop-loss reference$52.66
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$58.38MA60$59.08MA200$46.86
The technical indicators at the entry point show an RSI(14) of 67.2, approaching the overbought zone, with moving averages in a non-aligned state. The trading volume is 0.80 times the 20-day average, and the recent 7-day volatility has recorded +6.4%.
04
HISTORICAL EVIDENCE
Similar Past Cases
In the past, a similar case in the same stock (MRNA) recorded a return of 125.8% based on the same keyword 'personalized_cancer_vaccine', which serves as a positive reference. Additionally, while there is no direct similarity, for reference on top performance in the sector, there are cases of VEEE (return 451.7%, 2026-07-16) and LRCX (return 346.8%, 2026-07-06).
Reviewing Prediction vs. Actual Result
At the time of the forecast, a conservative or cautious approach was simulated based on the clinical news regarding the melanoma vaccine, along with a technical indicator showing an RSI(14) of 67.2, a non-aligned moving average, a trading volume of 0.80 times the 20-day average, and a recent 7-day volatility of +6.4%. However, the actual results significantly exceeded the predicted return of 7.5%, achieving a return of 125.8% and receiving an OVERHIT designation. This demonstrates that strong bio-innovation news can lead to explosive stock price increases in the actual market, surpassing short-term technical indicators or trading volume limitations.
What to Watch in the Next Analysis
Through this trading review, when powerful catalysts such as major clinical results occur, rather than conservatively predicting the upper limits based solely on simple technical indicators (such as non-aligned moving averages or somewhat high RSI), I will actively incorporate a strategy that allows for flexible responses, keeping the impact of positive news open for the next trade.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-08-20
$62.96Verification ChartVerification · 2026-08-20 13:47:23
125.8%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.